RxDoctor Payments Data

Kenneth Kohagen, MD

Gastroenterology · Raleigh, NCNPI 1972589935

Payments from drug & device makers

$6,866in general payments, 2019–2025

Across 324 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$1K
  • Boston Scientific$826
  • Intercept Pharmaceuticals, Inc.$570
  • Takeda Pharmaceuticals U.S.A., Inc.$286
  • Johnson & Johnson$258
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$6,848100%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,866 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$197,243
Medicare patients
367
Services billed
6,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin18$67,643
Mesalamine22$15,111
Ursodiol48$14,009
Dexlansoprazole DrDexlansoprazole26$9,693
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates125$8,089
SutabSod Sulf/Pot Chloride/Mag Sulf33$5,262
DexilantDexlansoprazole14$3,744
Pantoprazole Sodium192$3,651
Omeprazole200$2,872
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg112$2,780
Famotidine108$1,517
Esomeprazole Magnesium39$1,361
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag11$1,340
Lactulose13$570
Lansoprazole19$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$132$67,64318 claims
Braintree Laboratories, Inc.Sutab, Suflave$59$6,60244 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$286$3,74414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →